We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
-2.15%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$574M
AUM Growth
-$338M
Cap. Flow
-$522M
Cap. Flow %
-91.01%
Top 10 Hldgs %
44.83%
Holding
163
New
26
Increased
13
Reduced
41
Closed
50

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$12.3M
2
AMGN icon
Amgen
AMGN
+$11.3M
3
SLN
Silence Therapeutics
SLN
+$10.8M
4
VKTX icon
Viking Therapeutics
VKTX
+$9.06M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$6.59M

Top Sells

Rank Stock Value
1
CRBP icon
Corbus Pharmaceuticals
CRBP
+$10.5M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$10.4M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.14M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$7.96M
5
ANNX icon
Annexon
ANNX
+$5.3M

Sector Composition

Rank Sector Weight
1 Healthcare 55.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JSPR icon
51
Jasper Therapeutics
JSPR
$20M
$2.39M 0.42%
105,175
– –
LRMR icon
52
Larimar Therapeutics
LRMR
$377M
$2.35M 0.41%
323,528
-115,000
-26% -$881K
RCUS icon
53
Arcus Biosciences
RCUS
$3.33B
$2.21M 0.38%
+145,000
New +$2.34M
SANA icon
54
CALL
Sana Biotechnology
SANA
$882M
$2.18M 0.38%
+4,000
New +$31.9K
SANA icon
55
PUT
Sana Biotechnology
SANA
$882M
$2.18M 0.38%
+4,000
New +$31.9K
QTTB icon
56
Q32 Bio
QTTB
$435M
$1.96M 0.34%
109,094
+86,759
+388% +$2.08M
ELEV
57
DELISTED
Elevation Oncology
ELEV
$1.86M 0.32%
690,089
+542,000
+366% +$2.04M
ANNX icon
58
Annexon
ANNX
$796M
$1.86M 0.32%
380,000
-1,025,000
-73% -$5.3M
CMPS
59
Compass Pathways
CMPS
$1.47B
$1.83M 0.32%
+302,908
New +$2.38M
NKTR icon
60
Nektar Therapeutics
NKTR
$2.39B
$1.63M 0.28%
+87,494
New +$1.84M
SRRK icon
61
Scholar Rock
SRRK
$5.88B
$1.53M 0.27%
183,701
-108,000
-37% -$1.32M
SGMT icon
62
Sagimet Biosciences
SGMT
$435M
$1.41M 0.25%
412,565
– –
TRML
63
DELISTED
Tourmaline Bio
TRML
$1.4M 0.24%
108,483
– –
VRDN icon
64
CALL
Viridian Therapeutics
VRDN
$2.2B
$1.3M 0.23%
+1,000
New +$13.8K
IBIO icon
65
iBio
IBIO
$67.6M
$1.27M 0.22%
600,000
– –
IFRX icon
66
InflaRx
IFRX
$243M
$1.23M 0.21%
704,987
– –
PYXS icon
67
CALL
Pyxis Oncology
PYXS
$185M
$1.19M 0.21%
+3,586
New +$15.1K
ACHL
68
DELISTED
Achilles Therapeutics
ACHL
$1.18M 0.2%
1,443,181
– –
DFTX
69
Definium Therapeutics
DFTX
$5.6B
$1.17M 0.2%
162,481
-135,000
-45% -$1.18M
ITOS
70
DELISTED
iTeos Therapeutics
ITOS
$1.17M 0.2%
78,574
-22,751
-22% -$326K
GPCR icon
71
CALL
Structure Therapeutics
GPCR
$3.37B
$1.14M 0.2%
290
-1,710
-86% -$70.2K
GPCR icon
72
PUT
Structure Therapeutics
GPCR
$3.37B
$1.14M 0.2%
290
-120,110
-100% -$4.93M
KOD icon
73
Kodiak Sciences
KOD
$2.5B
$1.12M 0.2%
476,586
– –
ROIV icon
74
Roivant Sciences
ROIV
$23.6B
$1.06M 0.19%
100,609
– –
NUVB icon
75
Nuvation Bio
NUVB
$2.29B
$1.05M 0.18%
358,282
-275,000
-43% -$839K
1 2
3
4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Ikarian Capital held 163 positions worth $574M, down 37% from $912M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Ikarian Capital withdrew a net $522M in Q2 2024, closing 50 positions and reducing 41 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $10.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 40% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Enliven Therapeutics worth $13.7M.

  • Ikarian Capital's largest Q2 2024 buy was Enliven Therapeutics: 586,552 shares worth $13.7M.
  • Ikarian Capital added most to Sarepta Therapeutics in Q2 2024, an estimated $6.59M increase.
  • Ikarian Capital's biggest Q2 2024 reduction was Corbus Pharmaceuticals, cutting an estimated $10.5M.
  • Ikarian Capital fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $10.4M.
  • Ikarian Capital's ten largest holdings make up 45% of its $574M portfolio in Q2 2024.
  • Ikarian Capital opened 26 new positions and closed 50 in Q2 2024.
  • Ikarian Capital's portfolio value fell 37% quarter-over-quarter to $574M.

Based on Ikarian Capital's 13F filing for Q2 2024, filed 14 Aug 2024.